Citadel Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Citadel Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-71,300	Closed	-$5.37M	–	14226
2022 Q2	$5.37M	Buy	+71,300	New	+$3.17M	﹤0.01%	3667
2021 Q4	–	Sell	-4,200	Closed	-$279K	–	15313
2021 Q3	$279K	Buy	4,200 +600	+17%	+$42.7K	﹤0.01%	11214
2021 Q2	$281K	Sell	3,600 -600	-14%	-$44.3K	﹤0.01%	11422
2021 Q1	$397K	Sell	4,200 -7,200	-63%	-$856K	﹤0.01%	10198
2020 Q4	$1.39M	Buy	11,400 +7,900	+226%	+$866K	﹤0.01%	6093
2020 Q3	$306K	Buy	+3,500	New	+$244K	﹤0.01%	8105

Citadel Advisors's TPTX Position: Q3 2022 in Review

Citadel Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 165,650 shares — an estimated $12.5M sold.

Citadel Advisors first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $30.8M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Citadel Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 165,650 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $12.5M.
Citadel Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
Citadel Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $30.8M in Q4 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.